|

Numinus Wellness CEO Discusses MAPS Partnership & How Psychedelics Will Change Society

ByPsychedelic Spotlight



In this episode James, from The Psychedelic Investor, sits down with Numinus Wellness’ (OTC: NUMIF, TSX.V: NUMI) CEO Payton Nyquvest for the Psychedelic Spotlight Podcast.

Numinus is a Psychedelic Medicines company focused on scaling up psychedelic therapy. Perhaps most exciting is their partnership with MAPS, where the two companies are working together to provide MDMA assisted therapy to adults suffering from PTSD. Together they hope to answer the question: Can MDMA treat PTSD?

Numinus is also working with psilocybin, though they are growing natural psilocybin fungi to use, as opposed to most other companies which are using synthetic psilocybin. Numinus wants to use this natural psilocybin to treat addiction (substance use disorder). Can psilocybin treat addiction? Numinus wants to find out.

On top of all of this, Numinus also currently runs ketamine clinics to treat depression across Canada. Once MDMA therapy becomes legalized, Numinus will expand these clinics operations to include MDMA therapy for PTSD. Can ketamine treat depression? Numi is testing it!

Perhaps most interestingly. Payton of Numinus and James discussed how they thought society would change with the acceptance and eventual legalization of psychedelics. Would the world become a better place? One can only hypothesize.

Enjoy the episode!

#NuminusWellness #Numi #PaytonNyquvest

source

Similar Posts

  • MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]

    Listen, Videos

    MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
    Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.

    Also, there were 0 cases of serious adverse side effects in the MDMA group.

    So which companies will be the largest benefactors of these results?

    Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently

    2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.

    3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.

    4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.

    5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.

    Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
    Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
    Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
    Link to Numinus (NUMI): https://numinus.ca/
    Link to Atai Life Sceinces : https://www.atai.life/
    Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    Clinical trials :

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #NUMIStock

  • Interview With Lauren Taus

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.